Skip to main content
. 2004 Jan 20;90(2):436–442. doi: 10.1038/sj.bjc.6601531

Figure 3.

Figure 3

Survival curves of adenocarcinoma patients with low GalNAc-T3 expression or high GalNAc-T3 expression. (A) Overall survival (n=148), the overall 5-year survival rates in the patients with low GalNAc-T3 expression and high GalNAc-T3 expression were 25.4 and 72.1%, respectively (P<0.01). (B) Survival curves of stage I lung adenocarcinoma patients (n=78, P<0.01).